Every provider you look at for stubborn depression is really a bundle of tradeoffs. One takes your plan but is an hour away. Another is around the corner but self-pay. A third promises a fast start but offers something other than the FDA-approved treatment you read about. How do you weigh them?
A good place to start is with how other people weigh them. Our summer poll let 443 Midwest adults across ten states vote, twice each, on what a ketamine or esketamine clinic should offer. Below, those six factors go head to head, including what each costs you if you lean on it too hard, with every figure final and validated.
How the six factors ranked
- Insurance pays: 85 percent
- Nearby: 43 percent
- FDA approval in hand: 27 percent
- Speedy improvement: 24 percent
- Discretion: 11 percent
- Veteran and first responder focus: 10 percent
Each respondent picked two, so the column sums to 200 rather than 100.
Coverage versus distance
Why coverage wins: without it, most people cannot sustain treatment at all. Spravato, the approved esketamine spray for depression that resists treatment, means a series of supervised visits, a very different expense from one prescription. On a separate question, 65 percent of respondents called coverage big or decisive for trying it.
Why distance still matters: certified clinics are the only places that give esketamine, every dose comes with two hours or more of observation, and patients need a ride home. Across the Midwest, from rural Iowa and Nebraska to the far edges of Ohio and Indiana, the closest certified site can be a long drive. Every visit needs someone to take you.
When they conflict: a covered site you cannot reach is not much better than an uncovered one next door. Ask whether your plan covers rides to medical appointments, which many Medicaid plans do, and whether a covered site is on a route you already travel.
Coverage versus speed
The case for speed: depression is exhausting, and waiting weeks for authorization can feel unbearable.
The case for coverage: a fast start you cannot afford to continue may not help. And the survey suggests most people know it. On the tradeoff item, 51 percent of respondents sided with insurance despite the hoops, while cash for simplicity drew 23 percent and plain uncertainty 26 percent. Brain Recovery Centers publishes a plain overview of esketamine costs and coverage that helps put numbers on that choice.
A caution: no provider can promise fast results, or any result, for a particular person. Treat claims of speed as a scheduling promise, not a clinical one.
Speed versus approval
These two sat close in our respondents' ranking, 27 and 24 percent, but they can pull in opposite directions.
Self-pay ketamine clinics that offer IV infusions, and at-home ketamine programs, can sometimes start faster because they do not wait on insurance. But ketamine used this way is off-label for depression. It does not carry the FDA approval that esketamine has for treatment-resistant depression, and at-home programs involve less direct supervision.
If approval matters to you, and for many people it does, weigh that carefully. Rated on its own, FDA approval was big or deciding for 59 percent of respondents. When forced to pick only two priorities, people may have assumed approval came bundled with coverage. For esketamine that is often a reasonable assumption. For off-label ketamine, it is not.
Privacy versus everything else
Privacy ranked fifth, at 11 percent. That does not make it unimportant. For some people, particularly those in small towns where everyone knows everyone, discretion can be a real concern.
The good news is that privacy rarely requires giving up the top factors. You can ask any covered, nearby provider about waiting areas, private treatment rooms, and how they handle communication. If a provider leads its marketing with discretion but does not take your plan, that tells you something about priorities.
Specialty focus versus general care
Specialization in veterans or first responders ranked last, at 10 percent. Just 29 respondents, roughly 7 percent of the 443, had served as military members or first responders themselves, and a larger share had a relative who had.
If you are one, experience with trauma and service culture may matter a great deal. It is worth asking about. But you can usually find it within the covered, reachable options rather than trading them away for it.
Putting it together
A simple way to use the ranking:
- Filter by coverage. Drop anything your plan will not pay for, unless you have decided to self-pay.
- Sort by distance, counting your driver's time.
- Check approval status. Esketamine or off-label ketamine?
- Ask about how they track progress, rather than how fast they promise results.
- If privacy or specialized experience matters to you, raise it too.
Across the ten states in our survey, Medicaid and insurance rules differ from state to state, and a site just across a state line may not accept your state's Medicaid. Check before assuming the nearest site is available to you.
The factor not on the list
One thing did not appear among the six choices but shaped everything else: the recommendation of a doctor you trust. Asked whose advice would tip them toward trying it, 74 percent pointed to their own doctor. Only 2 percent said an ad. And for 56 percent of respondents, primary care would come before anyone else.
Bring your comparison to that doctor. They can tell you whether esketamine is appropriate for you in the first place, which no ranking can. Nothing in this piece is medical advice, and no treatment is certain to work.
If staying safe is the struggle, stop comparing. From any Midwest town, pick up the phone or open your texts and reach 988. Lifeline counselors (the Suicide and Crisis Lifeline) are on duty around the clock.
Methodology
The ranking comes from Pollfish survey 395586438. Panelists answered it until the June 23, 2026 close, and 443 finished, each between 18 and 64, from Iowa, Illinois, Indiana, Nebraska, Ohio, Minnesota, Kansas, Oklahoma, Missouri and Wisconsin. The provider question asked for two picks. Each figure spans all 443 respondents and is final. The publisher commissioned and funded this study.